Immunotherapy Benefits Highlight Week in Cancer News – Specialty Pharmacy Times
|
Immunotherapy Benefits Highlight Week in Cancer News
Specialty Pharmacy Times A supplemental biologics license application (sBLA) has been submitted to the FDA for the full regulatory approval of blinatumomab (Blincyto) as a treatment for patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-precursor acute … |
